Post-Hoc Live

Endpoints News

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: [email protected]

Сайт подкаста

Слушайте в своём приложении

Эпизоды

55 эпизодов

  1. The US midterm elections and biopharma 43:07
  2. Live from DC: Is secrecy the solution? 26:30
  3. Live from Boston: How pharma thinks about China 24:04
  4. The case for — and against — an AZ-BMS megadeal 35:10
  5. Record IPOs — with Parabilis and Kailera’s CEOs 33:54
  6. Are the China hawks winning? 42:22
  7. How much is everyone in biopharma getting paid? 32:38
  8. How to stabilize US biotech — with Dr. Jeremy Levin 32:56
  9. Makary's out: Live from the FT Summit 29:01
  10. Q1 earnings recap with Endpoints News 38:18
  11. Trust, MAHA, and what’s next for the CDC 34:15
  12. The spring deals bonanza 36:39
  13. Who won the Hims vs Novo feud? 28:24
  14. Moderna vs the FDA 30:03
  15. Hims, Novo, and a new front in the compounding wars 32:17
  16. Post-Hoc Live, Live! at #JPM26 with Noubar Afeyan 27:09
  17. Biopharma’s Winners and Losers of 2025 30:31
  18. The fight over Metsera 31:06
  19. Choosing the Endpoints 11 32:40
  20. mRNA vs MAHA — with Brett Giroir 39:58
  21. The Sarepta mess 36:50
  22. Sarepta’s very bad week 34:45
  23. On the ground at BIO 2025 32:48